Rajarshi Keshav, Chatterjee Aroni, Ray Shashikant
School of Community Science and Technology (SOCSAT) Indian Institute of Engineering Scince and Technology (IIEST), Shibpur, Howrah, West Bengal, 711103, India.
Indian Council of Medical Research (ICMR)-Virus Research Laboratory, NICED, Kolkata, India.
Biotechnol Rep (Amst). 2020 May 14;26:e00467. doi: 10.1016/j.btre.2020.e00467. eCollection 2020 Jun.
The COVID-19 disease is caused by a positive stranded RNA virus called SARS-CoV-2. The virus mainly targets the pulmonary epithelial cells as it's initial site of infection by letting its surface spike protein interact and bind to the host ACE2 receptor. The internalization and gradual replication of the virus results in an exaggerated immune response triggering release of many pro-inflammatory cytokines and chemokines. This immune storm is responsible for multiple health hazards in the host ultimately leading to multiple organ failure. Mesenchymal stem cell therapy offers a promising approach towards mitigating the delirious effects of the infection in the COVID-19 patients. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. This review has been organized to put forward the positive aruments and implications in support of mesenchymal stem cell therapy as a necessary approach for treating COVID-19 patients.
新冠肺炎是由一种名为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的正链RNA病毒引起的。该病毒主要通过其表面刺突蛋白与宿主血管紧张素转换酶2（ACE2）受体相互作用并结合，将肺上皮细胞作为其初始感染部位。病毒的内化和逐渐复制会引发过度的免疫反应，触发许多促炎细胞因子和趋化因子的释放。这种免疫风暴是宿主多种健康危害的原因，最终导致多器官功能衰竭。间充质干细胞疗法为减轻新冠肺炎患者感染的有害影响提供了一种有前景的方法。这种疗法已显示可降低新冠肺炎患者促炎细胞因子的表达，并修复受损组织。本综述旨在提出支持间充质干细胞疗法作为治疗新冠肺炎患者必要方法的积极论据和意义。
